Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00417248 · ClinicalTrials.gov registry record · Phase 1
Cisplatin/Etoposide/Radiotherapy Followed by Consolidation Sorafenib for Inoperable Stage III Non-Small Cell Lung Cancer
A Phase 1 study, sponsored by Nasser Hanna, M.D..
- Terminated
- Registry status
- Phase 1
- Development phase
- 8
- Enrollment target
NCT00417248 is a Phase 1 study that was terminated before completion, run by Nasser Hanna, M.D.. The registered enrollment target is 8 participants.
The verdict
NCT00417248, a Phase 1 study, was terminated before completion, sponsored by Nasser Hanna, M.D..
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 8 participants
- Enrollment target
Study Summary
Sorafenib has demonstrated in vivo anti-tumor efficacy. This trial will evaluate the safety and preliminary efficacy of sorafenib following chemoradiation in locally advanced NSCLC.
Interventions
- DRUG Cisplatin
- DRUG Etoposide
- DRUG Sorafenib
- PROCEDURE Radiotherapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2007-06 |
| Est. Completion | 2008-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00417248
The ClinicalTrials.gov registry entry for NCT00417248 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Nasser Hanna, M.D., which has 8 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Cisplatin is the first listed.
NCT00417248 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00417248 about?
NCT00417248 is a clinical study titled "Cisplatin/Etoposide/Radiotherapy Followed by Consolidation Sorafenib for Inoperable Stage III Non-Small Cell Lung Cancer". Sorafenib has demonstrated in vivo anti-tumor efficacy. This trial will evaluate the safety and preliminary efficacy of sorafenib following chemoradiation in locally advanced NSCLC.
What is the current status of trial NCT00417248?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 8 participants. The study started on 2007-06. Estimated completion is 2008-04.
What interventions are being tested in trial NCT00417248?
The interventions under investigation include: Cisplatin (DRUG), Etoposide (DRUG), Sorafenib (DRUG), Radiotherapy (PROCEDURE).
Who is sponsoring clinical trial NCT00417248?
This trial is sponsored by Nasser Hanna, M.D., which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.